WE
GLUE icon

Wealth Effects’s Monte Rosa Therapeutics GLUE Stock Holding History

Wealth Effects’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Hold
10,099
– – 0.06% 221
2025
Q4 		$158K Hold
10,099
– – 0.05% 208
2025
Q3 		$74.8K Buy
+10,099
New +$53.5K 0.02% 215

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Wealth Effects's GLUE Position: Q1 2026 in Review

Wealth Effects held its Monte Rosa Therapeutics (GLUE) position steady in Q1 2026 at 10,099 shares worth $166K. The position accounts for 0.06% of the portfolio, ranked #221.

Wealth Effects first reported a position in GLUE in Q3 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Wealth Effects held 10,099 shares of Monte Rosa Therapeutics worth $166K as of Q1 2026.
  • Wealth Effects left its Monte Rosa Therapeutics share count unchanged in Q1 2026.
  • Monte Rosa Therapeutics made up 0.06% of Wealth Effects's portfolio in Q1 2026, its #221 holding.
  • Wealth Effects first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Wealth Effects's 13F filing for Q1 2026, filed 21 Apr 2026.